Invitrogen Launches First Low-Cost Instruments; Portfolio Review on Track to Wrap Up This Year | GenomeWeb
Following years of speculation in the marketplace on when Invitrogen would reach beyond chemistry and service offerings and enter the instrument space, the firm this week launched the first two products in a planned series of low-cost, benchtop instruments.
 
Chairman and CEO Greg Lucier, speaking at the UBS Global Life Sciences Conference in New York this week, also said that the firm’s portfolio review, which could lead to some divestitures, is on track to be completed by the end of the year.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.